- Home
- CLNN vs BRNS Comparison
CLNN vs BRNS Comparison
Compare CLNN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | BRNS |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 30.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLNN | BRNS |
|---|---|---|
| Price | $4.36 | $0.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $33.75 | $4.00 |
| AVG Volume (30 Days) | ★ 119.0K | 99.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $200,000.00 | N/A |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $19,516.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.25 | $0.51 |
| 52 Week High | $13.50 | $1.83 |
Technical Indicators
Market Signals| Indicator | CLNN | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 60.28 |
| Support Level | $3.92 | $0.65 |
| Resistance Level | $4.70 | $0.74 |
| Average True Range (ATR) | 0.38 | 0.06 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 96.64 | 66.07 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.